Skip to main content
OpenTrials

Clinical trial condition

Hemostatic Disorders

Explore clinical trials studying Hemostatic Disorders. Study availability and eligibility vary by location and protocol.

3,072 public trials 579 recruiting studies
Refine in advanced search Browse all conditions

Hemostatic Disorders trial results

Active, Not Recruiting

Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom

NCT02952508

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Central Nervous System Lymphoma, +36 more
Locations
  • Cellectar Biosciences site Los Angeles, California, United States
  • Cellectar Biosciences site Redlands, California, United States
  • Cellectar Biosciences site Washington D.C., District of Columbia, United States
  • Cellectar Biosciences site Jacksonville, Florida, United States
View all 52 locations
View Trial Details
Active, Not Recruiting

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

NCT05257083

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of Arkansas Little Rock, Arkansas, United States
  • City of Hope Duarte, California, United States
  • UC San Diego Health Moores Cancer Center San Diego, California, United States
  • University of California San Francisco (UCSF) San Francisco, California, United States
View all 106 locations
View Trial Details
Active, Not Recruiting

Assess Safety and Efficacy of VAD044 in HHT Patients

NCT05406362

Conditions
Arteriovenous Malformations, Cardiovascular Abnormalities, Cardiovascular Diseases, +11 more
Locations
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Universitair Ziekenhuis Gent Ghent, Belgium
  • Hospices Civils de Lyon Lyon, France
  • Ospedale Maggiore di Crema Crema, Italy
View Trial Details
Active, Not Recruiting

Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma

NCT06353022

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • CH de la Côte Basque Bayonne, France
  • CHU Caen Caen, France
  • CHRU DIjon Dijon, France
  • Chd Vendee La Roche-sur-Yon, France
View all 19 locations
View Trial Details

Related conditions